Search Results - "Handula, Maryana"
-
1
IEDDA: An Attractive Bioorthogonal Reaction for Biomedical Applications
Published in Molecules (Basel, Switzerland) (30-07-2021)“…The pretargeting strategy has recently emerged in order to overcome the limitations of direct targeting, mainly in the field of radioimmunotherapy (RIT). This…”
Get full text
Journal Article -
2
Preclinical Evaluation of a PSMA-Targeting Homodimer with an Optimized Linker for Imaging of Prostate Cancer
Published in Molecules (Basel, Switzerland) (11-05-2023)“…Prostate-specific membrane antigen (PSMA) targeting radiopharmaceuticals have been successfully used for diagnosis and therapy of prostate cancer. Optimization…”
Get full text
Journal Article -
3
Orthogonal synthesis of a versatile building block for dual functionalization of targeting vectors
Published in Open Chemistry (15-07-2023)“…Dual functionalization of targeting vectors, such as peptides and antibodies, is still synthetically challenging despite the increasing demand for such…”
Get full text
Journal Article -
4
A Novel Luciferase-Based Reporter Gene Technology for Simultaneous Optical and Radionuclide Imaging of Cells
Published in International journal of molecular sciences (01-08-2024)“…Multimodality reporter gene imaging combines the sensitivity, resolution and translational potential of two or more signals. The approach has not been widely…”
Get full text
Journal Article -
5
Radiochemical and Biological Evaluation of 3p- C -NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
Published in Pharmaceuticals (Basel, Switzerland) (15-06-2023)“…Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic…”
Get full text
Journal Article -
6
Synthesis and Evaluation of Two Long-Acting SSTR2 Antagonists for Radionuclide Therapy of Neuroendocrine Tumors
Published in Pharmaceuticals (Basel, Switzerland) (01-09-2022)“…Somatostatin receptor subtype 2 (SSTR2) has become an essential target for radionuclide therapy of neuroendocrine tumors (NETs). JR11 was introduced as a…”
Get full text
Journal Article -
7
Synthesis and Evaluation of ePSMA-DM1: A New Theranostic Small-Molecule Drug Conjugate (T-SMDC) for Prostate Cancer
Published in Pharmaceuticals (Basel, Switzerland) (28-07-2023)“…Small-molecule drug conjugates (SMDCs) are compounds in which a therapeutic payload is conjugated to a targeting vector, for specific delivery to the tumor…”
Get full text
Journal Article -
8
[ 212 Pb]Pb-eSOMA-01: A Promising Radioligand for Targeted Alpha Therapy of Neuroendocrine Tumors
Published in Pharmaceuticals (Basel, Switzerland) (10-07-2023)“…Peptide receptor radionuclide therapy (PRRT) has been applied to the treatment of neuroendocrine tumors (NETs) for over two decades. However, improvement is…”
Get full text
Journal Article -
9
eTFC-01: a dual-labeled chelate-bridged tracer for SSTR2-positive tumors
Published in EJNMMI radiopharmacy and chemistry (22-05-2024)“…Background Integrating radioactive and optical imaging techniques can facilitate the prognosis and surgical guidance for cancer patients. Using a single…”
Get full text
Journal Article -
10
Towards Complete Tumor Resection: Novel Dual-Modality Probes for Improved Image-Guided Surgery of GRPR-Expressing Prostate Cancer
Published in Pharmaceutics (14-01-2022)“…Nuclear and optical dual-modality probes can be of great assistance in prostate cancer localization, providing the means for both preoperative nuclear imaging…”
Get full text
Journal Article -
11
First preclinical evaluation of [225Ac]Ac-DOTA-JR11 and comparison with [177Lu]Lu-DOTA-JR11, alpha versus beta radionuclide therapy of NETs
Published in EJNMMI radiopharmacy and chemistry (30-06-2023)“…Background The [ 177 Lu]Lu-DOTA-TATE mediated peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors (NETs) is sometimes leading to treatment…”
Get full text
Journal Article -
12
Development of C-terminal modified long-acting DOTA-JR11 analogs for optimized treatment of NETs
Published in Nuclear medicine and biology (01-11-2023)Get full text
Journal Article -
13
P-259 - Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors
Published in Nuclear medicine and biology (01-05-2022)Get full text
Journal Article -
14
Actinium-225 labeling of DOTATATE and DOTA-JR11 for the treatment of SSTR2-positive tumors
Published in Nuclear medicine and biology (01-05-2022)Get full text
Journal Article -
15
Preclinical evaluation of ePSMA-DM1: a PSMA-targeting theranostic small molecule drug conjugate
Published in Nuclear medicine and biology (01-11-2023)Get full text
Journal Article -
16
A novel clickable MSAP agent for dual fluorescence/nuclear labeling of biovectors
Published in Organic & biomolecular chemistry (12-08-2020)“…We herein describe the development of a novel dual-modality optical/radio-imaging agent for general and site-specific labeling of biovectors through a…”
Get more information
Journal Article -
17
P-260 - Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists
Published in Nuclear medicine and biology (01-05-2022)Get full text
Journal Article -
18
Albumin binders: a potential strategy for enhanced treatment of NETs using SSTR2 antagonists
Published in Nuclear medicine and biology (01-05-2022)Get full text
Journal Article -
19
Radiochemical and Biological Evaluation of 3p-IC/I-NETA-ePSMA-16, a Promising PSMA-Targeting Agent for Radiotheranostics
Published in Pharmaceuticals (Basel, Switzerland) (01-06-2023)“…Bifunctional chelators (BFCs) are a key element in the design of radiopharmaceuticals. By selecting a BFC that efficiently complexes diagnostic and therapeutic…”
Get full text
Journal Article -
20